Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma

Table 2 Univariate analysis of survival in gastric cancer according to clinicopathologic factors and PRL-3 expression

Variables	Patients (n)	5-year survival	P
Variables	Patients (n)	(% ± SD)	P
Age
<60	93	65.3% ± 0.056	0.716
≥60	103	63.1% ± 0.052
Sex
Male	146	81.5% ± 0.034	0.764
Female	50	50.3% ± 0.082
Diagnosis*
GC	177	83.1% ± 0.029	0.006
GEC	19	10.6% ± 0.092
TNM stage
I	33	74.3% ± 0.078	0.000
II	50	53.1% ± 0.239
III	92	52.1% ± 0.060
IV	21	15.6% ± 0.082
Tumor invasion
T1	20	50.0% ± 0.354	0.000
T2	27	53.1% ± 0.225
T3	78	53.8% ± 0.068
T4	71	35.3% ± 0.071
Lymph node metastasis
Negative	59	55.4% ± 0.145	0.000
N1	40	69.1% ± 0.091
N2	34	18.2% ± 0.064
N3	63	24.2% ± 0.075
Metastasis
Negative	175	86.1% ± 0.027	0.000
Positive	21	15.6% ± 0.082
Differentiation
Well	13	75.2% ± 0.126	0.278
Moderately	89	38.1% ± 0.075
Poor	94	55.2% ± 0.065
Histology
Adenocarcinoma	154	43.7% ± 0.057	0.191
Others	42	65.0% ± 0.091
Vascular invasion
Negative	123	58.3% ± 0.068	0.000
Positive	73	37.0% ± 0.063
PRL-3
Negative	114	51.7% ± 0.061	0.011
Positive	82	31.8% ± 0.090

*GC: Gastric cancer; GEC: Gastroesophageal Cancer. As expected, clinical TNM stage, depth of tumor invasion, lymph node status, metastasis, vascular invasion and tumor location were significantly associated with clinical outcome.

ISSN: 1479-5876